Hayley Chapman | Senior Program Director
Patient Focused Drug Development
As a Senior Program Director at Patient Focused Medicines Development (PFMD), I bring over 25 years of expertise in healthcare strategy, patient engagement, and transformative partnerships. Based in Canada, my work bridges the biopharmaceutical, medtech, and non-profit sectors, driving systemic change by enabling the patient voice into healthcare decision-making on a global scale.
A hallmark of my leadership is building trusting relationships that bridge people, ideas, and organizations to address complex societal challenges in healthcare. I believe that genuine collaboration—grounded in shared purpose and mutual respect—is the foundation for creating sustainable solutions and driving meaningful change.
Key 2024 Highlights:
- Led the development of PFMD’s Patient Engagement Intelligence project to better articulate the value of patient engagement, and to develop iterative processes to improve the quality of patient engagement initiatives
- Advanced patient-centered ESG metrics that align patient insights with investment and organizational decision-making
- Guided collaborations with global regulators like the FDA, EMA, and PMDA to integrate patient engagement into regulatory frameworks, as the lead of the global, multi-stakeholder, PFMD Patient Engagement & Patient Experience Data initiative
- Presented at high-impact conferences, including ICHOM and ISPOR, on advancing patient engagement practices and frameworks.
Appearances:
Day 1- World Orphan Drug Congress USA 2025 @ 14:00
Roundtable 1: From discovery to access: Harnessing patient engagement and patient experience data throughout the Rare Disease drug development journey & beyond
Every stakeholder in the rare disease ecosystem – from researchers, developers, regulators, and policymakers to healthcare professionals and patient organisations – aims to improve the health outcomes for patients. Yet, the voices, lived experiences and priorities of the rare disease patient community (including families, caregivers and loved ones) often go unheard.
At the same time, patient engagement (PE) and patient experience data (PED) are emerging as key enablers in research and healthcare to deliver evidence-based patient unmet needs, health outcomes and impact. Optimizing patient health outcomes through the integration of PE & PED across research and healthcare systems should now be a priority for all the stakeholders in the healthcare ecosystem.
How can we bridge this gap and ensure PED, integrated with PE, becomes a driving force in clinical development and healthcare decision-making in the rare disease space - addressing evidence-based patients’ unmet needs and priorities?
Join us for an engaging and open conversation on the role of PE and PED in rare diseases and share your insights and experiences on the value patient-driven data can bring patients, society and businesses.
Sponsored by Alfasigma.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events